Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders.

an allogeneic CAR-T therapy targeting CD19/CD20, has administered at the starting dose specified in the clinical protocol to the first patient with systemic lupus erythematosus (SLE) in an ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell ...

The acquisition will bolster CoinDesk's data offerings, including CoinDesk Indices and the CD20 index. CCData is a ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...

Odronextamab is an investigational bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 receptor expressed on the surface of T cells. This results in local T-cell ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

About ADI-001 ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for the treatment of autoimmune diseases. ADI-001 was granted Fast ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...